[度伐利尤单抗单药治疗非小细胞肺癌期间获得性血栓性血小板减少性紫癜]
[Acquired thrombotic thrombocytopenic purpura during durvalumab monotherapy for non-small cell lung cancer].
作者信息
Shimada Shotaro, Kuroiwa Kai, Narita Hinako, Okamura Reiko, Uesugi Yuka, Sasaki Yohei, Watanuki Megumi, Arai Nana, Kawaguchi Yukiko, Fujiwara Shun, Yanagisawa Koji, Hattori Norimichi
机构信息
Division of Hematology, Department of Medicine, Showa University School of Medicine.
出版信息
Rinsho Ketsueki. 2024;65(1):24-29. doi: 10.11406/rinketsu.65.24.
Immune checkpoint inhibitor (ICI)-induced thrombocytopenias are rare immune-related adverse events (irAE), but ICI-related thrombotic thrombocytopenic purpura (TTP) is extremely rare. A 79-year-old woman with non-small cell lung cancer received maintenance therapy with the anti-human PD-L1 monoclonal antibody durvalumab. Four weeks after the last infusion, she developed overt TTP. Remission was achieved by plasma exchange and prednisolone, and the patient has now been recurrence-free for over 12 months. To our knowledge, this is the first report of TTP occurring as an irAE of durvalumab.
免疫检查点抑制剂（ICI）引起的血小板减少是罕见的免疫相关不良事件（irAE），但ICI相关的血栓性血小板减少性紫癜（TTP）极为罕见。一名79岁的非小细胞肺癌女性接受了抗人PD-L1单克隆抗体度伐利尤单抗的维持治疗。最后一次输注四周后，她出现了明显的TTP。通过血浆置换和泼尼松龙实现了缓解，患者目前已无复发超过12个月。据我们所知，这是首例报道度伐利尤单抗的irAE导致TTP。
Zotero 插件